Working… Menu

Vorinostat and Palliative Radiotherapy (PRAVO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00455351
Recruitment Status : Completed
First Posted : April 3, 2007
Last Update Posted : July 22, 2011
Information provided by:
Oslo University Hospital

Brief Summary:
Phase I study. Side-effects when combined with standard palliative radiotherapy.

Condition or disease Intervention/treatment Phase
Pelvic Cancer Radiotherapy Drug: Vorinostat Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study on Suberoylanilide Hydroxyamic Acid (Vorinostat) a Histone Deacetylase Inhibitor, in Palliative Radiotherapy for Advanced Tumors.
Study Start Date : February 2007
Actual Study Completion Date : August 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Palliative Care
Drug Information available for: Vorinostat

Arm Intervention/treatment
Experimental: A I
Study drug
Drug: Vorinostat
Increasing dosing, phase I

Primary Outcome Measures :
  1. DLT [ Time Frame: continously ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Pelvic malignancy
  • Palliative radiation treatment planed
  • ECOG <3
  • Age>18 years

Exclusion Criteria:

  • Previous pelvic radiotherapy
  • Uncontrolled diarrhea
  • Insulin-dependent diabetes mellitus
  • BMI<18.5

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00455351

Layout table for location information
The Norwegian Radium Hospital
Oslo, Norway, NO-0310
Sponsors and Collaborators
Oslo University Hospital
Layout table for investigator information
Study Director: Sigbjørn Smeland, MD,PhD Norwegian Radium Hospital
Publications of Results:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Svein Dueland (PI), Rikshospitalet-Radiumhospitalet HF Identifier: NCT00455351    
Other Study ID Numbers: EudraCTnumber 2006-003631-76
First Posted: April 3, 2007    Key Record Dates
Last Update Posted: July 22, 2011
Last Verified: July 2011
Keywords provided by Oslo University Hospital:
Palliative treatment
Max. tolerable dose
Additional relevant MeSH terms:
Layout table for MeSH terms
Pelvic Neoplasms
Neoplasms by Site
Antineoplastic Agents
Histone Deacetylase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action